| 000 | 01702 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513154759.0 | ||
| 264 | 0 | _c19990216 | |
| 008 | 199902s 0 0 eng d | ||
| 022 | _a0305-7453 | ||
| 024 | 7 |
_a10.1093/jac/42.4.511 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBiron, P | |
| 245 | 0 | 0 |
_aCefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). _h[electronic resource] |
| 260 |
_bThe Journal of antimicrobial chemotherapy _cOct 1998 |
||
| 300 |
_a511-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aCefepime |
| 650 | 0 | 4 |
_aCephalosporins _xadministration & dosage |
| 650 | 0 | 4 |
_aCilastatin _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug Therapy, Combination _xadministration & dosage |
| 650 | 0 | 4 |
_aFever _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImipenem _xadministration & dosage |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNeutropenia _xchemically induced |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aFuhrmann, C | |
| 700 | 1 | _aCure, H | |
| 700 | 1 | _aViens, P | |
| 700 | 1 | _aLefebvre, D | |
| 700 | 1 | _aThyss, A | |
| 700 | 1 | _aViot, M | |
| 700 | 1 | _aSoler-Michel, P | |
| 700 | 1 | _aRollin, C | |
| 700 | 1 | _aGrès, J J | |
| 773 | 0 |
_tThe Journal of antimicrobial chemotherapy _gvol. 42 _gno. 4 _gp. 511-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/jac/42.4.511 _zAvailable from publisher's website |
| 999 |
_c9782953 _d9782953 |
||